![FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps – PharmaLive FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps – PharmaLive](https://www.pharmalive.com/wp-content/uploads/2020/09/Nucala-AutoInjectors_HighRes-1030x555.jpg)
FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps – PharmaLive
![GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease | Fierce Pharma GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1601298054/Nucala.jpg/Nucala.jpg?VersionId=r6Di4PzlKiMxU5HMu2sM9wRF4e4LxKBq)
GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease | Fierce Pharma
INSTRUCTIONS FOR USE NUCALA (mepolizumab) solution for injection in pre-filled pen (auto-injector) Administer once every 4 weeks
![Mepolizumab prefilled syringe and autoinjector: a profile of their use in severe eosinophilic asthma | SpringerLink Mepolizumab prefilled syringe and autoinjector: a profile of their use in severe eosinophilic asthma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40267-020-00711-3/MediaObjects/40267_2020_711_Fig1_HTML.png)